SCHEDULE 13G/A: EcoR1 Capital and Oleg Nodelman Disclose 5.0% Stake in Tectonic Therapeutic, Inc.

EcoR1 Capital, LLC and its control person Oleg Nodelman have filed an amended Schedule 13G, disclosing a beneficial ownership of 5.0% in Tectonic Therapeutic, Inc.'s common stock as of March 31, 2025.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Tectonic Therapeutic, Inc.
• As of March 31, 2025, EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 935,121 shares of Tectonic Therapeutic, Inc. common stock, representing 5.0% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 879,710 shares, representing 4.7% of the class.
• The percentages are calculated based on 18,662,672 shares of Common Stock outstanding on March 1, 2025, as reported in the Issuer's Form 10-K for the fiscal year ended December 31, 2024.
• The shares are held with shared voting and shared dispositive power by the reporting persons.
• The acquisition of securities was in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates significant institutional investment, which is generally a positive signal of confidence in the company. However, it's a routine disclosure and doesn't provide new operational or financial performance data.

Positives

• Significant institutional ownership by EcoR1 Capital, LLC and its affiliates, indicating investor interest in Tectonic Therapeutic, Inc.
• The filing confirms that the shares were acquired and are held in the ordinary course of business, not for control-influencing purposes.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Tectonic Therapeutic, Inc.'s future performance or strategic direction.

Management Comments

• The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

Schedule 13G filings are standard disclosures for passive institutional investors who acquire more than 5% of a company's stock. EcoR1 Capital is an investment firm specializing in healthcare and biotechnology, suggesting their investment in Tectonic Therapeutic, Inc. aligns with their sector focus.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership, common among institutional investors in the biotechnology and pharmaceutical sectors.
• It does not provide performance metrics for direct comparison to industry peers or projects. The 5% ownership threshold is a common benchmark for requiring such disclosures.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which may influence investor sentiment.
• Company Management: Awareness of a significant passive investor on their shareholder register.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G as required by changes in their beneficial ownership or if their investment intent changes.

Key Dates

Keywords

Tectonic Therapeutic Inc., EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Healthcare Investment